MedTrace Logo

Improving Cognition With Neurodegradation Countermeasure

NCT05715073 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-11-29

No results posted yet for this study

Summary

The goal of this randomized, placebo-controlled, three-condition, double-blind, within-participants crossover clinical trial is to compare caffeine, TeaCrine plus caffeine, and a placebo condition in ROTC or tactical personnel.

The main question it aims to answer is the effect of the condition on measures of cognitive performance, cardio-autonomic, and hemodynamic responses after a physically demanding protocol.

The physiological function will be derived from metrics of heart rate variability, whilst cogntive performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.

Participants will report to the lab 4 times, once for familiarization of cognitive measures and then 3 times for their experimental visits. Participants will consume their randomized condition an hour prior to the fatiguing interval exercise protocol. Following they will complete a series of cognitive tasks.

Conditions

  • Hemodynamics
  • Caffeine
  • TeaCrine
  • Cognitive Change

Interventions

DIETARY_SUPPLEMENT

TeaCrine and Caffeine

Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.

DIETARY_SUPPLEMENT

Caffeine

Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.

OTHER

Placebo

Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.

Sponsors & Collaborators

  • University of South Carolina

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-11-01
Completion
2023-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05715073 on ClinicalTrials.gov